Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 6, 2010, Pages 367-374

  Graefe Mody, U ^a   Huettner, S ^a   Stahle H ^a   Ring, A ^a   Dugi, K A ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

BI 1356; CYP3A4; Interaction; Linagliptin; Simvastatin

Indexed keywords

8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; CYTOCHROME P450 3A4; DRUG METABOLITE; SIMVASTATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; GLYCEMIC CONTROL; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; PATIENT SAFETY; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77952770226     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48367     Document Type: Article

References (25)

1. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformintreated patients with type 2 diabetes. Diabetes Care. 2004; 27: 2874-2880. (Pubitemid 39565052)
2. Ahrén B, Pacini G, Foley JE, Scheweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005; 28: 1936-1940. (Pubitemid 41060966)
3. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000; 68: 122-129. (Pubitemid 30659167)
4. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2010; 19: 133-140.
5. FDA Draft Guidance on Drug Interactions. USFDA Center for Biologics Evaluation and Research (CBER), September 2006.Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm093606.htm (accessed 11 January 2010).
6. Fuchs H, Tillement JP, Urien S, Geischel A, Roth W. Concentration- dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol. 2009; 61: 55-62.
7. Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009; 25: 1963-1972.
8. Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol. 1999; 84: 811-815.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002; 360: 7-22.
10. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamic and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase 4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009; 11: 786-789.
11. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008; 48: 1171-1178.
12. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998; 64: 177-182. (Pubitemid 28423853)
13. Krishna R, Garg A, Jin B, Keshavarz SS, Bieberdorf FA, Chodakewitz J, Wagner JA. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteyl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009; 67: 520-526.
14. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther. 1998; 64: 477-483. (Pubitemid 28531591)
15. Lilja JJ, Kivisto KT and Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther. 2000; 68: 384-390.
16. Mari A, Sallas WM, He YL, Watson C, Liqueros- Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90: 4888-4894. (Pubitemid 41159387)
17. Marino MR, Vachharajani NN, Hadjilambris OW. Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. J Clin Pharmacol. 2000; 40: 875-879.
18. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet. 1993; 24: 195-202.
19. Mousa O, Brater DC, Sunblad KJ and Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000; 67: 267-274.
20. Neuvonen PJ, Kantola T and Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP 3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998; 63: 332-334. (Pubitemid 28182231)
21. Pham DQ, Nogid A, Plakogiannis R. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. Am J Health Syst Pharm. 2008; 65: 521-531. (Pubitemid 351429713)
22. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008; 16: CD006739. (Pubitemid 351807276)
23. Ristic S, Byiers S, Foley J, Homes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005; 7: 692-698. (Pubitemid 41601073)
24. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin- 1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin- 2-ylmethyl)-3,7-dihydro-purine-2,6- dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008; 325: 175-182.
25. Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, Woerle H-J, Dugi KA. DPP-4 Inhibitor Linagliptin Improves Glycemic Control in Type 2 Diabetic Patients when added to Ongoing Metformin Therapy. Diabetes. 2009; 58 (Suppl): 535 (abstract).